Literature DB >> 7845401

Reliability among neurologists in the severity assessment of blepharospasm and oromandibular dystonia: a multicenter study.

G Defazio1, V Lepore, G Abbruzzese, E Barontini, A Berardelli, T Caraceni, F Carella, P Girlanda, M Manfredi, C Messina.   

Abstract

The reliability of a scale of 0 to 4 (where 0 is normal) in rating the severity of blepharospasm (BS) and oromandibular dystonia (OMD) was evaluated by the concordance among six neurologists from different neurological institutions. As expressed by k index, interobserver agreement was moderate either for BS or for OMD according to the Landis classification. Neurologists showed different rating attitude toward BS and OMD. In fact, the category analysis showed that raters were inclined to overestimate BS and to underestimate OMD. The familiarity with dystonia influenced reliability more than the length of professional experience in neurology. In fact, when examiners were subdivided into subgroups (each of three raters) according to the former criteria, the level of interobserver agreement increased significantly. Almost perfect agreement was obtained in intrarater comparisons. These results may be of value with regard to the conduct of multicenter epidemiologic and clinical studies on focal dystonias.

Entities:  

Mesh:

Year:  1994        PMID: 7845401     DOI: 10.1002/mds.870090606

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  2 in total

1.  Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group.

Authors:  G Defazio; A Berardelli; G Abbruzzese; V Coviello; F Carella; M T De Berardinis; G Galardi; P Girlanda; S Maurri; M Mucchiut; A Albanese; M Basciani; L Bertolasi; R Liguori; N Tambasco; L Santoro; G Assennato; P Livrea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-11       Impact factor: 10.154

2.  Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia.

Authors:  Laura M Scorr; Michael R Silver; John Hanfelt; Elaine Sperin; Alan Freeman; H A Jinnah; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.